Asenapine treatment and health-related quality of life in patients experiencing bipolar i disorder with mixed episodes: Post-hoc analyses of pivotal trials

Current Medical Research and Opinion

Volumn 30, Issue 4, 2014, Pages 711-718

  Michalak, E E ^a   Guiraud Diawara, A ^b   Sapin, C ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Lundbeck   (France)

Author keywords

Asenapine; Bipolar I disorder; Health related quality of life; Mixed episodes; Olanzapine

Indexed keywords

ASENAPINE; OLANZAPINE; PLACEBO; FUSED HETEROCYCLIC RINGS; NEUROLEPTIC AGENT;

ARTICLE; BIPOLAR I DISORDER; CLINICAL FEATURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MIXED MANIA AND DEPRESSION; POST HOC ANALYSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT FORM 36; SOCIAL INTERACTION; ADULT; BIPOLAR DISORDER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; MIDDLE AGED;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; FEMALE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE;

EID: 84896456662     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.874988     Document Type: Article

References (34)

1. First MBFA, Pincus HA. DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders-IV: Text Revision) Handbook of Differential Diagnosis. American Psychiatric Press Inc., 2002
2. Castle DJ. Bipolar mixed states: still mixed up? Curr Opin Psychiatry 2014;27:38-42
3. Dilsaver SC, Chen YW, Swann AC, et al. Suicidality, panic disorder and psychosis in bipolar depression, depressive-mania and pure-mania. Psychiatry Res 1997;73:47-56
4. Osby U, Tiainen A, Backlund L, et al. Psychiatric admissions and hospitalization costs in bipolar disorder in Sweden. J Affect Disord 2009;115:315-22
5. Michalak EE, Murray G, CREST.BD. Development of the QoL.BD: a disorderspecific scale to assess quality of life in bipolar disorder. Bipolar Disord 2010;12:727-40
6. Sajatovic M, Jenkins JH, Cassidy KA, et al. Medication treatment perceptions, concerns and expectations among depressed individuals with Type I Bipolar Disorder. J Affect Disord 2009;115:360-6
7. Zimmerman M, McGlinchey JB, Posternak MA, et al. How should remission from depression be defined? The depressed patient's perspective. Am J Psychiatry 2006;163:148-50
8. Hope ML, Page AC, Hooke GR. The value of adding the Quality of Life Enjoyment and Satisfaction Questionnaire to outcome assessments of psychiatric inpatients with mood and affective disorders. Qual Life Res 2009;18:647-55
9. Michalak EE, Yatham LN, Lam RW. Quality of life in bipolar disorder: a review of the literature. Health Qual Life Outcomes 2005;3:72
10. Namjoshi MA, Buesching DP. A review of the health-related quality of life literature in bipolar disorder. Qual Life Res 2001;10:105-15
11. Dean BB, Gerner D, Gerner RH. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. Curr Med Res Opin 2004;20:139-54
12. Revicki DA, Matza LS, Flood E, et al. Bipolar disorder and health-related quality of life: review of burden of disease and clinical trials. Pharmacoeconomics 2005;23:583-94
13. Michalak EE, Yatham LN, Kolesar S, et al. Bipolar disorder and quality of life: a patient-centered perspective. Qual Life Res 2006;15:25-37
14. Murray G, Michalak EE. The quality of life construct in bipolar disorder research and practice: past, present, and possible futures. Bipolar Disord 2012;14:793-6
15. Shi L, Namjoshi MA, Zhang F, et al. Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status. Int Clin Psychopharmacol 2002;17:227-37
16. Namjoshi MA, Rajamannar G, Jacobs T, et al. Economic, clinical, and qualityof- life outcomes associated with olanzapine treatment in mania: results from a randomized trial. J Affect Disord 2002;69:109-18
17. Revicki DA, Paramore LC, Sommerville KW, et al. Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. J Clin Psychiatry 2003;64:288-94
18. Saphris (asenapine sublingual tablets). Whitehouse Station, NJ: Schering Corporation, subsidiary of Merck & Co. Inc., 2010
19. European Medicines Agency: Sycrest (asenapine). Available at: http://www. ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 001177/human-med-001379.jsp&mid=WC0b01ac058001d124 [Last accessed 29 November 2013]
20. McIntyre RS, Cohen M, Zhao J, et al. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord 2010;122:27-38
21. McIntyre RS, Cohen M, Zhao J, et al. A 3-week, randomized, placebocontrolled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 2009;11:673-86
22. Azorin JM, Sapin C, Weiller E. Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses. J Affect Disord 2013;145:62-9
23. Maruish M (ed.). User's manual for the SF-36v2 Health Survey, 3rd edn. Lincoln: QualityMetric Inc., 2012
24. IsHak WW, Brown K, Aye SS, et al. Health-related quality of life in bipolar disorder. Bipolar Disord 2012;14:6-18
25. Michalak EE, Murray G, Young AH, et al. Burden of bipolar depression: impact of disorder and medications on quality of life. CNS Drugs 2008;22:389-406
26. Dikeos D, Badr MG, Yang F, et al. Twelve-month prospective, multinational, observational study of factors associated with recovery from mania in bipolar disorder in patients treated with atypical antipsychotics. World J Biol Psychiatry 2010;11:667-76
27. Sapin C, Corson H, Hansen K. The effect of asenapine on health-related quality of life in patients with manic or mixed episodes associated with bipolar I disorder. 2nd International Congress on Neurobiology, Psychopharmacology & Treatment Guidance, Thessaloniki (Greece), 24-27 Nov 2011
28. Solomon DA, Leon AC, Endicott J, et al. Empirical typology of bipolar I mood episodes. Br J Psychiatry 2009;195:525-30
29. Suppes T, Marangell LB, Bernstein IH, et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. J Affect Disord 2008;111:334-43
30. Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006;20: 536-46
31. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999;156:702-9
32. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry 2000;57:841-9
33. Zhang H, Wisniewski SR, Bauer MS, et al. Comparisons of perceived quality of life across clinical states in bipolar disorder: data from the first 2000 Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) participants. Compr Psychiatry 2006;47:161-8
34. Leidy NK, Palmer C, Murray M, et al. Health-related quality of life assessment in euthymic and depressed patients with bipolar disorder. Psychometric performance of four self-report measures. J Affect Disord 1998;48:207-14